(NASDAQ: ITOS) Iteos Therapeutics's forecast annual revenue growth rate of 49.65% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Iteos Therapeutics's revenue in 2025 is $35,000,000.On average, 1 Wall Street analysts forecast ITOS's revenue for 2025 to be $1,431,822,671, with the lowest ITOS revenue forecast at $1,431,822,671, and the highest ITOS revenue forecast at $1,431,822,671. On average, 2 Wall Street analysts forecast ITOS's revenue for 2026 to be $932,923,753, with the lowest ITOS revenue forecast at $574,106,925, and the highest ITOS revenue forecast at $1,291,740,581.
In 2027, ITOS is forecast to generate $5,840,963,855 in revenue, with the lowest revenue forecast at $5,840,963,855 and the highest revenue forecast at $5,840,963,855.